In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias S. Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold, Nordic Myeloma Study Group
Abstract
Lytic bone destruction is one of the most devastating complications in Multiple Myeloma (MM). At diagnosis, more than half of patients have bone pain, and 90 percent of all patients with MM will experience bone destruction that may cause pain, pathological fractures, nerve root compression, hypercalcemia and potentially spinal cord compression [ 1 ].
Topics & Concepts
Zoledronic acidMultiple myelomaMedicineBone diseaseDiseaseInternal medicineProgressive diseaseOncologyOsteoporosisMultiple Myeloma Research and TreatmentsBone health and treatmentsMyeloproliferative Neoplasms: Diagnosis and Treatment